No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ACLX240517C50000
- 1.00
- -2.70-72.97%
15min DelayClose May 10 15:59 ET
1.00High1.00Low
1.00Open3.70Pre Close10 Volume328 Open Interest50.00Strike Price1.00KTurnover49.06%IV2.53%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry1.00Time Value100Contract SizeAmericanOptions Type0.4787Delta0.1436Gamma49.74Leverage Ratio-0.1273Theta0.0029Rho23.81Eff Leverage0.0225Vega
Intraday
- 5D
- 1D
News
Buy Rating Affirmed for Arcellx Inc. Amidst Promising Trial Progress and Strategic Partnerships
Arcellx, Inc. (NASDAQ:ACLX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Arcellx, Inc. (NASDAQ:ACLX) just released its quarterly report and things are looking bullish. The results were impressive, with revenues of US$39m exceeding analyst forecasts by 90%, and statuto
Arcellx First Quarter 2024 Earnings: Beats Expectations
Express News | Needham Reiterates Buy on Arcellx, Maintains $81 Price Target
Arcellx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 64.42% Needham → $81 Reiterates Buy → Buy 05/07/2024 64.42% Needham → $81 Reiterates Buy → Buy
Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
Comments
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
大家加油
The analyst community exhibits a heightened bullish sentiment about Arcellx following substantial upgrades in next year's revenue and loss forecasts. Although the company's revenue growth is projected to decelerate, it's still anticipated to outpace the industry growth.
$Procter & Gamble(PG.US$ Downgraded to Hold From Buy at Truist
Procter & Gamble Price Target Cut to $155.00/Share From $165.00 by Truist Securities.
Roth Capital Upgrades $Snap-on(SNA.US$to Buy From Neutral, Adjusts Price Target to $298 From $278
Snap-On (SNA) has an average rating of hold and price targets ranging from $190 to $302, according to analysts polled by Capital IQ.
Truist Securities Initiates Coverage of $Arcellx(ACLX.US$ ...
Procter & Gamble Price Target Cut to $155.00/Share From $165.00 by Truist Securities.
Roth Capital Upgrades $Snap-on(SNA.US$to Buy From Neutral, Adjusts Price Target to $298 From $278
Snap-On (SNA) has an average rating of hold and price targets ranging from $190 to $302, according to analysts polled by Capital IQ.
Truist Securities Initiates Coverage of $Arcellx(ACLX.US$ ...
14
Read more